Sublingual immunotherapy: Update 2006

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 6, 2006, Pages 449-454

  Passalacqua, Giovanni ^a,b   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Padiglione Maragliano ^*  (Italy)

Author keywords

Efficacy; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; GRASS POLLEN ALLERGEN; HOUSE DUST ALLERGEN; PARIETARIA ALLERGEN; POLLEN ANTIGEN; RAGWEED ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION TEST; META ANALYSIS; NAUSEA; NONHUMAN; ORAL PRURITUS; PATIENT COMPLIANCE; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; STOMACH PAIN; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; THROAT IRRITATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ASTHMA; HUMANS; IMMUNOTHERAPY; PATIENT COMPLIANCE;

EID: 33750799865     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000246617.41871.40     Document Type: Review

References (61)

1. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing. J Allergy Clin Immunol 2001; 113:1129-1136.
2. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004; 113:1117-1121.
3. Malling HJ, Weeke B, editors. EAACI immunotherapy position paper. Allergy 1993; 48(suppl. 44): S64.
4. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986; 16:483-491.
5. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:437-448.
6. Bousquet J, Lockey R, Malling HJ, editors. World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53(Suppl.): 1-33.
7. Bousquet J, Van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(Suppl. 5): S146-S150.
8. Passalacqua G, Guerra L, Pasquali M, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004; 93:3-12.
9. Passalacqua G, Lombardi C, Canonica GW. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol 2004; 4:31-36.
10. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59:491-497.
11. Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498-504.
12. Smith H, White P, Annila I, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114:831-837.
13. Rolinck-Werninghaus C, Wolf H, Liebke C, et al. A prospective, randomized, double-blind, placebo-controlled multicentre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004; 59:1285-1293.
14. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93:425-430.
15. Dahl R, Stender H, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-190.
16. Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100:1374-1383. A very large double-blind placebo-controlled study in paediatric patients confirming the clinical efficacy of SLIT in asthmatic children with mite allergy.
17. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double blind controlled study with sublingual carbamylated allergoid in mild rhinitis due to mites. Allergy 2006; 61:849-854.
18. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809. One of the largest double-blind placebo-controlled studies with SLIT administered as tablets. This multicentre trial involved more than 800 patients and also assessed the dose response.
19. Marogna M, Spadolini I, Massolo A, et al. Clinical functional and immunological effects of sublingual immunotherapy in birch allergy. J Allergy Clin Immunol 2005; 115:1184-1188.
20. Pajno G, Passalacqua G, Vita D, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004; 59:883-887.
21. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis. Allergy 2005; 60:3-8. The first meta-analysis of the clinical efficacy of SLIT in adults and children, limited to rhinitis because of the paucity of data about asthma.
22. Penagos M, Compalati E, Baena Cagnani R, et al. Meta analysis of sublingual immunotherapy in pediatric patients. Ann Allergy Asthma Immunol 2006; 97: In press.
23. Di Rienzo V, Pagani A, Parmiani S, et al. Postmarketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999; 54:1110-1113.
24. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001; 56:889-892.
25. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergol Immunopathol 2004; 32:76-81.
26. Pajno GB, Peroni DG, Vita D, et al. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5:777-781.
27. Agostinis F, Tellarini L, Falagiani P, et al. Safety of SLIT in very young children. Allergy 2005; 60:133.
28. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95:254-258.
29. Di Rienzo V, Minelli M, Musarra A, et al. Postmarketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35:560-564. A large postmarketing survey of the safety of SLIT in children aged between 3 and 5 years, also showing the good safety profile in small children.
30. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181-184. An important and very interesting assessment of the safety in a dose-response controlled trial.
31. Gidaro GB, Frati F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:565-571.
32. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-514.
33. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005; 116:1073-1079. This is the first placebo-controlled randomized study showing the efficacy and clinical value of SLIT also for food allergy.
34. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-294.
35. Marcucci F, Sensi L, Di Cara G, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sublingual immunotherapy. Pediatr Allergy Immunol 2005; 16:519-526.
36. Rolinck-Werninghaus C, Kopp M, Liebke C, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-141.
37. Dehlink E, Eiwegger T, Gerstmayr M, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-39.
38. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10- production. Clin Exp Allergy 2006; 36:261-272. New acquisitions on the mechanism of action of SLIT.
39. Ciprandi G, Fenoglio D, Cirillo I, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95:38-44.
40. Ippoliti F, De Sanctis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-221.
41. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; In press.
42. Moingeon P, Batard T, Fadel R, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-165. This is a comprehensive and updated review on the ascertained and possible mechanism of action of SLIT.
43. Bagnasco M, Passalacqua G, Villa G. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31:54-60.
44. Bagnasco M, Altrinetti V, Pesce G, et al. Pharmacokinetics of radioalbelled Der p2 allergen and monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005; 138:197-202. An interesting study of the biodistribution of mite allergens in humans.
45. Pajno G, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
46. Purello D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31:1295-1302.
47. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002; 109:251-256.
48. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of SLIT for respirtory alllergy in real life: clinical efficacy and more. Allergy 2004; 59:1205-1210.
49. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857.
50. Osterberg L, Blashke T. Adherence to medication. N Engl J Med 2005; 353:487-497. A comprehensive review on the problems of adherence.
51. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004; 113:1219-1220.
52. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with a simplified SLIT regimen in real life. J Allergy Clin Immunol 2006; 117:946-948. A quantitative measurement of the adherence to SLIT in real life in more than 400 adult patients.
53. Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005; 116:1380-1381.
54. Cistero Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Invest Allergol Clin Immunol 2004; 14:17-25.
55. Roelofs-Haarhuis K, Wu X, Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 2004; 173:1043-1050.
56. Rossi R, Monasterolo RE. A pilot study of feasibility of ultra-rush (20-25 min) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18:277-285.
57. Tripodi S, Di Rienzo Businco A, Benincori N, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2005; 139:149-152.
58. Guerra L, Compalati E, Rogkakou A, et al. Randomized open comparison of the safety of SLIT in a no updosing and traditional updosing schedule in patients with parietaria allergy. Allergol Immunopathol 2006; 34:82-83.
59. Rodriguez F, Boquete M, Ibanez MD, et al. Once daily sublingual immunotherapy without updosing - a new treatment schedule. Int Arch Allergy Immunol 2006; 140:321-326.
60. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-1035. A complete and extensive review of the clinical characteristics of SLIT from the published study with a partial acceptance of the treatment from United States scientists.
61. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy 2006; 61:149-150.